All In Biotech

Drug Trial Radar · NCT07791901

MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial

High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 20, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
University of CalgaryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Providence Care, Kingston, ON, Canada
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot clinical trial will study psilocybin-assisted therapy for adults with advanced cancer who are experiencing demoralization, existential distress, or related psychological concerns. Demoralization can include feelings of hopelessness, helplessness, loss of meaning, and distress related to illness or end of life. The purpose of this study is to assess whether a hybrid group-based psilocybin-assisted therapy program is feasible, acceptable, and safe in adults with advanced cancer. The study will also explore which combination of psilocybin dose and psychotherapy approach may be most promising for a future larger trial. Participants will be randomly assigned by wave to one of four intervention combinations: 25 mg psilocybin with mindfulness-based psilocybin-assisted therapy, 25 mg psilocybin with standard psilocybin-assisted therapy, 5 mg psilocybin with mindfulness-based psilocybin-assisted therapy, or 5 mg psilocybin with standard psilocybin-assisted therapy. The psilocybin dose will be blinded, meaning participants and some members of the study team will not know which dose was assigned. Psychotherapy approach will not be blinded. The study will enroll at least 60 participants across Calgary and Kingston.

Conditions

  • Advanced Cancer
  • Demoralization
  • Existential Distress
  • Psychological Distress

Interventions

  • PEX010 25 mg psilocybinDrug

    Participants randomized to this dose condition will receive a single 25 mg oral dose of PEX010 (psilocybin) during a monitored in-person group dosing session, together with protocol-defined psychotherapeutic support

  • PEX010 5 mg psilocybinDrug

    Participants randomized to this dose condition will receive a single 5 mg oral dose of PEX010 (psilocybin) during a monitored in-person group dosing session, together with protocol-defined psychotherapeutic support. This is a blinded low-dose active comparator condition.

  • Standard Psilocybin-Assisted TherapyBehavioral

    Participants randomized to this psychotherapy condition will receive standard psilocybin-assisted therapy, including protocol-defined preparation, dosing-day support, and integration sessions. The intervention is delivered in a hybrid format, with some sessions conducted in person and some virtually, depending on session type and site logistics.

  • Mindfulness-Based Psilocybin-Assisted TherapyBehavioral

    Participants randomized to this psychotherapy condition will receive mindfulness-based psilocybin-assisted therapy, including protocol-defined preparation, dosing-day support, and integration sessions. The intervention includes mindfulness-based therapeutic elements and is delivered in a hybrid format, with some sessions conducted in person and some virtually, depending on session type and site logistics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Trial Feasibility Based on Prespecified RED/YELLOW/GREEN Progression CriteriaTime frame: From initial referral/screening through the 3-month follow-up (A5), up to approximately 4 months
  2. Incidence of Adverse Events (AEs)Time frame: From informed consent through the 3-month follow-up (A5), approximately up to 4 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Arthur Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Providence Care Hospital

    Kingston, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.